Abstract 16698: Comparison of Hospital Length of Stay Between Hospitalized Non-Valvular Atrial Fibrillation Patients Treated With Either Apixaban or Warfarin
Amanda M. Farr(Truven Health Analytics (United States)), John Graham(Bristol-Myers Squibb (United States)), Jeffrey Trocio(Pfizer (United States)), Stephen S. Johnston(Johnson & Johnson (United States)), Shalabh Singhal(Integrated BioTherapeutics (United States)), Yonghua Jing(AbbVie (United States))
Cited by 2
Related Papers
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
|Annals of the Rheumatic Diseases|2022|212
Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study
|Nature Communications|2020|107
Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long‐Term Warfarin Therapy
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2007|93